Oral formulation for the treatment of cardiovascular diseases

An orally administrable pharmaceutical dosage form for use in the prevention and/or treatment of a cardiovascular disease comprising:

• (a) acetylsalicylic acid as a first active agent;
• and
• (b) HMG-CoA reductase inhibitor as a second active agent, wherein said HMG-CoA reductase inhibitor is selected from atorvastatin and rosuvastatin and salts thereof, and wherein
• (a) are two or more single separate coated dosage units comprising one or more water-soluble polymer in said coating and being said coating substantially free from a water-insoluble polymer or an enteric polymer which means in an amount ranging between 0 to 5% by weight of the composition of the coating;
• and wherein the amount of coating is comprised from 8 to 12 mg/cm2;
• and showing a non-modified release profile;
• and
• (b) is one or more single separate coated dosage units;
• the dosage units are in the form of tablets, and
• the water soluble polymer is present in an amount by weight above 40% of the total weight of the coating and is selected from the group consisting of a water-soluble polyvinyl derivative selected from polyvinyl pyrrolidone, partly hydrolyzed polyvinyl alcohol, polyvinyl alcohol, and mixtures thereof.